Oncotarget is now offering Free Altmetric Article Reports as a new part of our Journal platform to provide real-time tracking of article coverage in digtial and traditional media channels, often long before traditional citations begin to accrue. Here are some resources where you can learn more about: Altmetric Analytic Software , Adding Altmetric data to your NIH Biosketch, What is the Altmetric donut , and How is your Altmetric score calculated
Two members of the Editorial Board of Oncotarget, William G. Kaelin, Jr. and Gregg L. Semenza, won 2016 Lasker Award for the discovery of the oxygen-sensing pathway.
Since 2010, Oncotarget has published 370 papers on oxygen-related topics. Gregg Semenza has published 7 papers in Oncotarget
See more on Oncotarget in global News
Oncotarget is launching sections (and accepting papers) on topics beyond oncology:
Impact factor (IF)
ISI/Thomson Reuters JCR
Starting August 2015, Oncotarget goes weekly
2015/2016: 5-Year Impact Factor: 5.415
2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology
Oncotarget ranks number 1 on Total Documents (2015) among all journals in Oncology, see here
If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.
The term "oncotarget" encompasses all molecules, pathways, and cellular functions common in cancer and aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes.
Oncotarget is a multidisciplinary traditional journal with free-access. Oncotarget publishes papers online in weekly issues. Each issue or paper can be printed for special demand.
Our mission is to make scientific results rapidly and widely available. To maximize the impact of research via insightful review. To allow exceptional discoveries to be shared quickly. To eliminate the border between specialties. To link different fields of biomedical science. To foster applications of basic and clinical science to fight disease.
Under the leadership of the most prominent scientists, the journal helps all researchers contribute to the progress of science. Life without disease is our ultimate goal.
The success of Oncotarget has prompted us to launch sections beyond oncology.
100 Plus Papers from the Editorial Board:
See full list
Copyright @ 2016 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC